MedTrace Logo

A Phase I Clinical Study of HLX3902 in Patients With mCRPC and Other Advanced Tumours

NCT07533708 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2026-04-16

No results posted yet for this study

Summary

This study is an open-label first-in-human phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HLX3902 in patients with mCRPC and other advanced solid tumours.

Conditions

  • mCRPC or Advanced/Metastatic Solid Tumors

Interventions

DRUG

HLX3902

HLX3902 will be administered as an intravenous (IV) infusion.

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-25
Primary Completion
2027-06-29
Completion
2028-05-24

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07533708 on ClinicalTrials.gov